Chardan Reiterates Sell On Esperion Therapeutics, Sees At Least 6 Reasons To Beware

By: via Benzinga
In a report published Wednesday, Chardan Capital Markets analyst Gbola Amusa maintained a Sell rating on Esperion Therapeutics Inc ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.